AMSBIO has launched a comprehensive range of cytosections that offer a verified, reproducible and renewable source of positive / negative controls where the expression of the target biomarker is confirmed for accuracy and specificity by an immunoassay.Researchers, antibody and assay developers as well as Immunohistochemistry (IHC) labs often find it difficult to find a reliable and verified source of positive / negative controls for their IHC experiments. This is especially important when they are developing new IHC protocols for novel targets whose expression pattern is not known…
BERLIN, Germany, April 14, 2021 – LINK Medical, the Northern European clinical research organization (CRO), is continuing the expansion of its German presence. This further strengthens their position as a gateway between the Nordics and one of the largest medical device and pharmaceutical markets in Europe. By establishing a stronger position in Germany, LINK Medical’s global clients get access to Germany’s well-recognized regulatory authorities, its vast network of clinical trial sites and investigators, and Europe’s largest patient population – all key elements for performing high-quality…
30/03/2021 Cambridge UK – SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed Series A funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut platform technology (the bionic nanoparticle) from UCLB. The company now has exclusive PolyNaut rights in all indications.
The funding round was jointly led by Meltwind and Origin Capital and had follow on investment from all existing investors including Abcam and o2H Ventures. The success of this funding round is…
Cambridge, United Kingdom and Singapore – 13 April 2021- Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a strategic partnership with Camtech Diagnostics (“Camtech”), a technology company providing total solutions to the biodefence, food and clinical diagnostics sectors. The partnership covers the distribution of Congenica’s platform in Asia-Pacific.
Under the partnership agreement Camtech will be responsible for the marketing, distribution and sales of Congenica’s clinical decision support…
NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.
HHBE has the ability to rapidly identify and isolate entire biosynthetic pathways from members of the plant kingdom and…
Research Triangle Park, NC, USA and Cambridge, UK, 10 April 2021 -- Inivata, a leader in liquid biopsy, today unveils new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting in support of the capabilities and application of the Company’s liquid biopsy technologies, particularly the RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence.
In two studies, RaDaR demonstrated excellent specificity (100%) and sensitivity (100%) in detecting MRD in patient cohorts with head and neck cancer and early-stage breast cancer. The data are available…
April 2021, Cambridge, UK – o2h Ventures, a UK based fund manager through investment in its SEIS and EIS human health funds is excited to announce an investment into Stingray Bio Ltd, a new spin out from the University of Sussex supported by the Sussex Innovation Centre.
Stingray Bio is developing new novel small molecule inhibitors of the LMTK3 kinase signaling pathway to treat breast and other cancers. Stingray’s drug target rationale has been extensively validated by its founders, Professors Georgios Giamas and John Spencer of the University of Sussex.
Stingray Bio targets the neglected…
CAMBRIDGE, UK and NEW YORK, USA, 7 April March 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’ Radioligand Therapies (RLT).
Under the three-year collaboration, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, and receive worldwide…
PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out Synomics Ltd. Synomics will develop and market applications of the PrecisionLife® combinatorial analytics platform for the improvement of the health and yield of livestock and crops in sustainable agriculture and food production. Wheatsheaf Group, PrecisionLife’s lead investor has invested in Synomics, with PrecisionLife retaining a minority equity holding.
Synomics licensed PrecisionLife’s platform following successful projects that proved that it outperforms established statistical genetics…